GTBP
GT Biopharma, Inc.Company Information
- Company Name
- GT Biopharma, Inc.
- CIK
- CIK0000109657
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- GTBP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- GTBP
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-04-11
- Last sale
- 2020-12-22
- Shares purchased (TTM)
- 100,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,978,073
- Shares outstanding
- 38,820,657
- Ownership
- 5.10%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -18.58%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 5 | 9 | 7 | 3 | 5 | 2 | 4 | 6 | 9 | 2 | 1 | 3 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | 8 | 13 | 13 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Deferred Offering Costs | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 6 | 10 | 8 | 4 | 7 | 3 | 4 | 7 | 9 | 10 | 14 | 16 | ||||||
| Assets | - | - | 8 | - | - | - | 4 | 7 | 9 | 10 | 14 | 16 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Operating Lease Right Of Use Asset | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Deposits Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Accounts Payable Current | 1 | 0 | 1 | 1 | 1 | 2 | 4 | 3 | 2 | 3 | 4 | 4 | ||||||
| Accrued Liabilities Current | 1 | 2 | 2 | 0 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Dividends Payable Current | - | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 2 | 2 | 2 | 1 | 31 | 4 | 6 | 5 | 4 | 5 | 7 | 5 | ||||||
| Liabilities | - | - | - | - | - | - | - | - | - | 5 | 7 | 6 | ||||||
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | ||||||||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | 2 | - | - | - | - | - | - | - | ||||||
| Preferred Stock Value | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 735 | 734 | 730 | 721 | 700 | 695 | 694 | 694 | 694 | 690 | 690 | 689 | ||||||
| Retained Earnings Accumulated Deficit | -731 | -727 | -724 | -718 | -726 | -696 | -695 | -691 | -688 | -684 | -682 | -679 | ||||||
| Stockholders Equity | 4 | 8 | 6 | 3 | -26 | -1 | -2 | 2 | 6 | 5 | 7 | 10 | ||||||
| Liabilities And Stockholders Equity | 6 | 10 | 8 | 4 | 7 | 3 | 4 | 7 | 9 | 10 | 14 | 16 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 45 | 35 | 26 | 6 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 45 | 35 | 26 | 6 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGT Biopharma, Inc. (GTBP) — SEC Financial Statements & Analysis
GT Biopharma, Inc. (GTBP) is a pharmaceutical preparations company, incorporated in DE. GT Biopharma, Inc. trades on Nasdaq as: GTBP. GT Biopharma, Inc. (GTBP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, GT Biopharma, Inc. carries a market cap of $19.02M, a P/E ratio of -1.67x, a P/B ratio of 5.33x, an enterprise value of $13.97M, and an EV/EBITDA multiple of -0.85x. On profitability, it posts a Return on Equity (ROE) of 102.04%, a Return on Assets (ROA) of -176.27%, and a Return on Invested Capital (ROIC) of -282.98%. Per share, it reports EPS of $-0.29, diluted EPS of $-0.29, free cash flow per share of $-0.37, and a dividend per share of $0.01. Over the trailing year, it posted net income growth of -70.22% year-over-year and EPS growth of -97.87% year-over-year. On the balance sheet, it maintains a current ratio of 2.61x, a quick ratio of 2.51x, working capital of $3.57M, a debt-to-equity ratio of 0.62x, a debt ratio of 0.38, an interest coverage ratio of -128.64x, free cash flow of $-14.43M (TTM), and net debt of $-5.05M. Figures sourced from SEC EDGAR.
- Market Cap
- $19.02M
- P/E TTM
- -1.67x
- EPS TTM
- $-0.29
- P/B TTM
- 5.33x
- ROE TTM
- 102.04%
- ROA TTM
- -176.27%
- Debt To Equity
- 0.62x
- Free Cash Flow TTM
- $-14.43M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is GT Biopharma, Inc. in?
GT Biopharma, Inc. (GTBP) operates in the Pharmaceutical Preparations industry.
What exchange does GTBP trade on?
GT Biopharma, Inc. (GTBP) trades on the Nasdaq.
Where is GT Biopharma, Inc. incorporated?
GT Biopharma, Inc. is incorporated in DE.
When was GT Biopharma, Inc. (GTBP)'s most recent SEC filing?
GT Biopharma, Inc. (GTBP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is GTBP's market cap?
GT Biopharma, Inc. (GTBP) has a market capitalization of $19.02M as of 2026-06-30.
What is GTBP's EPS (earnings per share)?
GT Biopharma, Inc. (GTBP)'s trailing twelve month EPS is $-0.29 as of 2026-06-30.
What is GTBP's ROE (return on equity)?
GT Biopharma, Inc. (GTBP)'s trailing twelve month Return on Equity (ROE) is 102.04% as of 2026-06-30.
What is GTBP's ROA (return on assets)?
GT Biopharma, Inc. (GTBP)'s trailing twelve month Return on Assets (ROA) is -176.27% as of 2026-06-30.
What is GTBP's ROIC (return on invested capital)?
GT Biopharma, Inc. (GTBP)'s trailing twelve month Return on Invested Capital (ROIC) is -282.98% as of 2024-03-31.
What is GTBP's EV/EBITDA?
GT Biopharma, Inc. (GTBP)'s trailing twelve month EV/EBITDA is -0.85x as of 2026-06-30.